Employees: 987
Size Hubei Biocause Heilen Pharmaceutical (301211.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $619M, the 3172nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥10.00 on 18 Nov 2026.
Performance Over six months the shares fell 10.0%, against -25.9% for the median peer and -20.0% for the China market (cap-weighted) — 4th highest of 20 in its peer set.
Growth Revenue grew 13.5% over the last twelve months (peer median +4.6%); the operating margin is 4.1% (peer median 4.4%).
Valuation It trades at 5.3× enterprise value to sales against a peer median of 3.0× (7th most expensive of 16).
Capital Return on invested capital runs 5.4 points below its cost of capital (10.7% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥489M | CN¥451M | CN¥445M | CN¥659M | CN¥513M |
| Revenue growth | — | +1% | -33% | +29% | — |
| Gross profit | CN¥148M | CN¥90.9M | CN¥122M | CN¥257M | CN¥142M |
| EBITDA | n/a | CN¥47.5M | CN¥56.6M | CN¥167M | CN¥96.9M |
| Net income | CN¥53.6M | CN¥34.9M | CN¥91.5M | CN¥176M | CN¥126M |
| Free cash flow | -CN¥44.5M | -CN¥29.0M | -CN¥63.9M | -CN¥49.5M | CN¥175M |
| Capital expenditure | CN¥64.4M | CN¥52.3M | CN¥164M | CN¥187M | CN¥76.0M |
| Total debt | CN¥1.54M | CN¥14.4M | CN¥19.2M | CN¥24.8M | CN¥19.8M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 301211.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -12.9% | -10.7% | 5th lowest of 20 |
| 6-month return | -10.0% | -25.9% | 4th highest of 20 |
| Distance from 52-week high | -41.0% | -39.9% | 10th lowest of 20 |
| Revenue growth (TTM) | +13.5% | +4.6% | 5th highest of 16 |
| Operating margin | 4.1% | 4.4% | 7th lowest of 15 |
| EV / Sales | 5.3× | 3.0× | 7th most expensive of 16 |
| ROIC minus cost of capital | -5.4 pp | -3.9 pp | 6th lowest of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hubei Biocause Heilen Pharmaceutical 301211.SZ | China | $619M | -10% | +13% | 4% | 5.3× | n/a | n/a |
| Olema Pharmaceuticals OLMA | United States | $619M | -49% | n/a | n/a | n/a | n/a | n/a |
| Bicara Therapeutics BCAX | United States | $623M | -54% | n/a | n/a | n/a | n/a | n/a |
| TTY Biopharm 4105.TWO | Taiwan | $615M | +10% | +5% | 29% | 3.0× | -8.7% | +8.8% |
| Orchid Pharma ORCHPHARMA.NS | India | $613M | +30% | +11% | 0% | 6.1× | n/a | n/a |
| Fuan Pharmaceutical (Group) 300194.SZ | China | $612M | -14% | -3% | -1% | 2.4× | 10.9% | -5.9% |
| Zhejiang Anglikang Pharmaceutical 002940.SZ | China | $612M | -52% | -13% | 10% | 3.3× | 10.1% | +2.1% |
| HeiLongJiang ZBD Pharmaceutical 603567.SS | China | $610M | -39% | -82% | n/a | 25.1× | 9.1% | -25.1% |
| Achieve Life Sciences QUIT | United States | $609M | n/a | n/a | n/a | n/a | n/a | n/a |
| Luoxin Pharmaceuticals Group Stock 002793.SZ | China | $609M | -26% | -10% | -9% | 2.0× | -1.0% | -17.9% |
| Chongkundang 185750.KS | South Korea | $609M | -27% | +6% | 4% | 0.5× | -6.6% | +5.4% |
| Arbutus Biopharma ABUS | United States | $630M | -6% | +1,143% | 80% | 1.6× | n/a | n/a |
| Zhejiang Wecome Pharmaceutical 300878.SZ | China | $632M | -18% | +92% | -41% | 16.9× | n/a | n/a |
| DBV Technologies DBV.PA | France | $604M | -46% | n/a | n/a | n/a | n/a | n/a |
| Shandong Jincheng Pharmaceutical 300233.SZ | China | $604M | -31% | +2% | 4% | 1.2× | -0.6% | -1.6% |
| Hangzhou Bio-Sincerity Pharma-Tech 301096.SZ | China | $602M | -38% | +5% | -30% | 7.5× | n/a | n/a |
| Center Laboratories 4123.TWO | Taiwan | $639M | -29% | +14% | 9% | 12.8× | 36.3% | +16.2% |
| JIANMIN PHARMACEUTICAL 600976.SS | China | $598M | -14% | -2% | 8% | 0.9× | -6.2% | +6.5% |
| Beijing Beilu Pharmaceutical 300016.SZ | China | $641M | -19% | +23% | 11% | 3.0× | 9.1% | +7.9% |
| Hainan Haiyao 000566.SZ | China | $642M | -18% | -18% | -50% | 10.6× | n/a | n/a |
| Immix Biopharma IMMX | United States | $596M | -20% | n/a | n/a | n/a | n/a | n/a |